trending Market Intelligence /marketintelligence/en/news-insights/trending/AdJH4i3138Qv2-xaYX6Oog2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Shanghai Fudan-zhangjiang Bio-Pharmaceutical plans dual listing in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Shanghai Fudan-zhangjiang Bio-Pharmaceutical plans dual listing in China

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. is planning a dual-listing of its shares on the Sci-Tech Innovation Board, the Shanghai Stock Exchange's new trading board for biotech companies.

The Hong Kong-listed company is also looking to raise proceeds of about 650 million Chinese yuan in an issuance of not more than 120 million A shares. The A shares will be offered to qualified price consultation participants and to other qualified investors of the Sci-Tech Innovation Board.

The company will use about 230 million Chinese yuan of the proceeds to register Hemoporfin, its drug used to treat a skin condition known as port wine stain, in the U.S. About 240 million Chinese yuan will go to its innovational research and sustainable development projects related to biological medicine.

Meanwhile, 180 million Chinese yuan is allocated for the acquisition of minor equity interests in Taizhou FudanZhangjiang Pharmaceutical Co. Ltd.

The shares issuance is subject to the receipt of approvals from the company's stockholders, China Securities Regulatory Commission and the Shanghai Stock Exchange. Following completion, the company's A shares will be listed and traded on the Sci-Tech Innovation Board.

As of March 13, US$1 was equivalent to about 6.71 Chinese yuan.